Oncothyreon enjoys Puma's success

|By:, SA News Editor

Shares of Oncothyreon (ONTY +16.1%) jump on 7x surge in volume today. The cancer therapeutics firm also has a HER2 inhibitor (ONT-380) in development.

Investors are falling all over themselves to buy into Puma Biotechnology (PBYI +292.5%) after it announced positive results from a Phase 3 clinical trial evaluating its HER2 inhibitor PB272 (neratinib) as a treatment for breast cancer.